Mechanisms of endocrine-resistance and therapeutic breakthroughs in hormone receptor-positive, HER2-negative breast cancer
10.12092/j.issn.1009-2501.2023.08.002
- Author:
Huyunlong ZHANG
1
;
Xiuzhi ZHU
1
;
Xi JIN
1
;
Zhimin SHAO
1
Author Information
1. Department of Breast Surgery, Fudan University Shanghai Cancer Center, Fudan University Breast Cancer Institute, Department of Oncology, Shanghai Medical College, Fudan University
- Publication Type:Journal Article
- Keywords:
breast cancer;
endocrine-resistance;
estrogen receptor;
targeted therapy
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2023;28(8):854-865
- CountryChina
- Language:Chinese
-
Abstract:
Breast cancers that are positive for hormone receptor but negative for human epidermal growth factor receptor 2 (abbreviated as HR+/HER2-) account for approximately 60% of total cases. Targeting estrogen signaling is one of the most important therapeutic strategies for HR+/HER2- breast cancer. However, the management of endocrine-resistant HR+/HER2- breast cancer remains a difficult issue in clinical practice. Previous multi-omic analysis and translational research have identified the mechanisms underlying endocrine-resistance including genomic alteration and abnormal epigenetic modification. To overcome endocrine-resistance, we have established a comprehensive and coherent therapeutic strategy. In addition, several novel therapies have shown promising efficacy in previous clinical trials and will emerge as alternative options for targeting endocrine-resistant HR+/HER2- breast cancer. In this review, we will introduce the mechanisms of endocrine-resistance, explain the current therapeutic strategy for endocrine-resistant HR +/HER2 - breast cancer and discuss the possible targeted therapies in the future.
